Physician profile
John R Stabile
NPI 1225042278
$2,459.58
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $468 · 2020: $478 · 2021: $680 · 2022: $696 · 2023: $16.19 · 2024: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $138.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $887.08 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $280.90 | 2020-2024 | |
| Alcon Vision LLC | $213.26 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $174.48 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $156.60 | 2021-2022 | |
| Amgen INC. | $124.99 | 2020 | |
| Coopervision INC. | $120.65 | 2020-2022 | |
| Abbvie INC. | $105.36 | 2022-2024 | Durysta |
| Aerie Pharmaceuticals, INC. | $83.51 | 2019-2021 | |
| Oyster Point Pharma, INC. | $81.41 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $71.47 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $55.89 | 2019-2022 | |
| Shire North American Group INC | $26.12 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $23.07 | 2019 | |
| Ocular Therapeutix, INC. | $14.93 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $14.65 | 2021 | |
| Bausch & Lomb Americas INC. | $12.85 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $12.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Stabile listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.